Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE StudyBrian Bressler, Gerassimos J. Mantzaris, Andrés Yarur et al.|Journal of Crohn s and Colitis|2021Cited by 148
215 Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVEPeter Higgins, Silvio Danese, Fabio Cataldi et al.|The American Journal of Gastroenterology|2019Cited by 1